IBJNews

Roche Diagnostics to get indirect boon from new test

Back to TopCommentsE-mailPrintBookmark and Share

Last week's U.S. approval of a new Roche drug-diagnostic combo for skin cancer won't by itself produce much revenue for its diagnostic division, but it could indirectly be a boon for the company's U.S. diagnostic headquarters in Indianapolis.

The U.S. Food and Drug Administration approved a new genetic test to go along with a new Roche melanoma drug on Aug. 17. The BRAF V600 Mutation Test for use in Roche’s cobas 4800 fluid analyzers will determine which patients are eligible for treatment with Zelboraf, the new medicine for patients with late-stage, metastatic melanoma, the most dangerous type of skin cancer.

The approval of the drug and test together is a first in U.S. history, although many pharmaceutical and diagnostic firms are working to achieve the same feat.

“That really to me substantiates what Roche has been saying for several years, that personalized health care is ... critical for the future,” Jack Phillips, CEO of Roche Diagnostics’ U.S. operations, said in an interview.

The money in this approval will come from the drug, which will sell for about $113,000 for a year’s treatment, according to an Aug. 17 report by Goldman Sachs Group Inc. Goldman analysts project Zelboraf could reach sales of $535 million by 2015, with other analysts saying it eventually could approach $1 billion per year.

Nearly 70,000 Americans are diagnosed with metastatic melanoma each year. But the number of patients that are in late stages of the disease and have the BRAF V600 mutation likely will only be about 7,000 per year, Deutsche Bank analyst Tim Race wrote in an Aug. 17 report.

Roche Diagnostics will sell the BRAF test for about $120 to $150 for each time it’s run, Phillips said. So if Deutsche Bank’s estimates are correct, the test would generate about $1 million a year in revenue.

But the real value to Roche Diagnostics is if it helps sell more cobas 4800 machines to laboratories, which will then run all of Roche’s other tests. The cobas 4800 runs a variety of DNA-based tests, such as ones for Chlamydia and gonorrhea, as well as for the human papillomavirus, or HPV.

“It really hits medical value and hits a home run around medical value,” Phillips said. He added, “That creates big demand for one test, but it will also drive customers to bring in Roche’s platform to run all our other tests.”

Not to mention that each cobas 4800 system costs between $250,000 and $300,000.

The new combination was developed in California, where Roche Diagnostics’ molecular research and development team is and where Roche subsidiary Genentech Inc. developed the drug. Roche's corporate headquarters is in Basel, Switzerland.

But sales of the test and the cobas 4800 will be handled out of the Indianapolis office.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Socialized medicine works great for white people in Scandanavia. It works well in Costa Rica for a population that is partly white and partly mestizo. I don't really see Obamacare as something aimed against whites. I think that is a Republican canard designed to elicit support from white people for republican candidates who don't care about them any more than democrats care about the non-whites they pander to with their phony maneuvers. But what is different between Costa Rica nd the Scandanavian nations on one hand and the US on the other? SIZE. Maybe the US is just too damn big. Maybe it just needs to be divided into smaller self governing pieces like when the old Holy Roman Empire was dismantled. Maybe we are always trying the same set of solutions for different kinds of people as if we were all the same. Oh-- I know-- that is liberal dogma, that we are all the same. Which is the most idiotic American notion going right back to the propaganda of 1776. All men are different and their differences are myriad and that which is different is not equal. The state which pretends men are all the same is going to force men to be the same. That is what America does here, that is what we do in our stupid overseas wars, that is how we destroy true diversity and true difference, and we are all as different groups of folks, feeling the pains of how capitalism is grinding us down into equally insignificant proletarian microconsumers with no other identity whether we like it or not. And the Marxists had this much right about the War of Independence: it was fundamentally a war of capitalist against feudal systems. America has been about big money since day one and whatever gets in the way is crushed. Health care is just another market and Obamacare, to the extent that it Rationalizes and makes more uniform a market which should actually be really different in nature and delivery from place to place-- well that will serve the interests of the biggest capitalist stakeholders in health care which is not Walmart for Gosh Sakes it is the INSURANCE INDUSTRY. CUI BONO Obamacare? The insurance industry. So republicans drop the delusion pro capitalist scales from your eyes this has almost nothing to do with race or "socialism" it has to do mostly with what the INSURANCE INDUSTRY wants to have happen in order to make their lives and profits easier.

  2. Read the article - the reason they can't justify staying is they have too many medicare/medicaid patients and the re-imbursements for transporting these patient is so low.

  3. I would not vote for Bayh if he did run. I also wouldn't vote for Pence. My guess is that Bayh does not have the stomach to oppose persons on the far left or far right. Also, outside of capitalizing on his time as U. S. Senator (and his wife's time as a board member to several companies) I don't know if he is willing to fight for anything. If people who claim to be in the middle walk away from fights with the right and left wing, what are we left with? Extremes. It's probably best for Bayh if he does not have the stomach for the fight but the result is no middle ground.

  4. JK - I meant that the results don't ring true. I also questioned the 10-year-old study because so much in the "health care system" has changed since the study was made. Moreover, it was hard to get to any overall conclusion or observation with the article. But....don't be defensive given my comments; I still think you do the best job of any journalist in the area shedding light and insight on important health care issues.

  5. Probably a good idea he doesn't run. I for one do not want someone who lives in VIRGINIA to be the governor. He gave it some thought, but he likes Virginia too much. What a name I cannot say on this site! The way these people think and operate amuses me.

ADVERTISEMENT